The approval dossier for Europe was submitted to the European Medicines Agency EMA at the end of while the dossier for Singapore was submitted at the beginning of Other regulatory filings are in the process of being finalised, in particular for the USA and Switzerland. Preparations for the launch and marketing with the partner Fresenius Medical Care are on schedule.
Successful inspections. Under the system of periodic audits and product pre-approvals, the St. Vifor Pharma Consumer Healthcare Following a difficult start to the year, business improved in the second half, largely thanks to Vifor Pharma's key markets. This downward trend is largely attributable to optimisation of the product range to exclude products that were no longer part of the core business, a declining market Third-party manufacturing increased year-on-year by Production of this new multiple sclerosis drug from Biogen Idec offers interesting growth opportunities.
Customers reward market performance. Thanks in part to the new, rapid picking lines, Galexis can ensure on-schedule delivery of all available medications within just a few hours throughout Switzerland. One specialised Galexis service that was much in demand in the year under review was support for pharmaceutical partners in supplying drugs for clinical studies. Alloga continued to successfully press ahead with the launch of the new coolbox.
Over 4, are now in circulation. Sales increased by 6. Growth was sustained by further expansion, high-priced medications from MediService's Pharma Care business unit and increasing volumes of prescriptions in the pharmacies. Expansion of the pharmacy network. In total, the GaleniCare pharmacy network expanded by 11 stores to own pharmacies and comprised points of sale including Amavita and Winconcept partner pharmacies at the end of Winconcept also gained six new partners, thereby expanding to a total of partner pharmacies.
Following rapid growth in recent years, Amavita harmonised its product range and defined a core range for the various formats and pharmacy sizes. The reorganised pharmacies are showing a marked improvement in sales. Two jubilees and one other milestone were also celebrated: the 40th anniversary of Sun Store, the 15th anniversary of MediService and the opening of the 50th Coop Vitality pharmacy.
Sun Store customers were able to take advantage of many special offers and competitions during the anniversary year, including the weekly "Sunny Monday" special promotion, which was so successful that it will be continued in New drug information publication platform. Documed won the European WTO tender from Swissmedic in and was thus awarded the contract to develop a new regulatory drug information publication platform Arzneimittelinformation Publikationsplattform Swissmedic AIPS , which became operational on 1 January All data links and products that are supplementary to the legal publication requirements will continue to be offered and invoiced according to cost.
Although these companies have a strong market position, Galenica is not aware of any abuse of this position and hopes that the situation will be clarified shortly. Following this successful implementation, a start was made on installing the software in Sun Store pharmacies. Dates for the diary The Galenica Group will announce the results of the financial year on 12 March A large part of the Group's income is generated by international operations. Log in. E-mail Password Remember Forgot password? Sign up.
New member. United States. United Kingdom. Schweiz DE. Suisse FR. Latest News. Listed company. Sector News. Our View. All Analysis.
- FISP: Institute for inter-cultural addiction prevention and health promotion. Zürich, Switzerland
Stock Picks. All stock picks. My Portfolio. Stock Screener Home. Technical Analysis. My Watchlists. Top News. To the best of our knowledge, we are the first to assess the welfare effects of innovative drugs in Switzerland. Another such evaluation has already been performed in the Netherlands, which revealed great potential welfare gains of introducing new pharmaceuticals to the market 1.
This evaluation and published report by Tsiachristas et al. The aim of the exploratory study was to establish knowledge in the welfare impact of innovative drugs introduced to the Dutch market after to reflect a year time horizon. A limited number of studies have been also collected from the scientific literature and in total, 52 studies were included.
The heterogeneous and foreign studies have been roughly adjusted to the Dutch situation by using purchasing power parities PPP and the deflator of the gross domestic product GDP as it is difficult to adjust for varying cost calculation methods and other country-specific aspects of a pharmacoeconomic evaluation.
Further details of the methodology have already been extensively described in the report 1. Our approach was to estimate the welfare impact of a basket of novel and innovative drugs in Switzerland for the year , which were launched onward. The parameters needed for these calculations were derived from published literature. A restrictive literature search based on the results of Tsiachristas et al. The search focused on cost-effectiveness and cost—utility analyses, respectively. References from the beginning of the study up to 31st October were included.
The included studies were restricted to English and German language. The search focused on publications reporting CEA of new drugs launched onward in Switzerland. Titles, abstracts, and finally full-texts of the articles found within the search were screened to assess the eligibility of those cost-effectiveness, respectively, cost—utility analyses.
Arzneimittel-Kompendium der Schweiz
Studies that fulfilled the following pre-defined inclusion criteria were considered:. For our analysis, it would have been more accurate to consider only studies from a societal perspective The societal perspective includes not only the direct cost such as drug costs, hospitalization costs, or costs for a physician visit, but also considers the indirect cost, e.
The literature search identified only few studies from a societal perspective that met the inclusion criteria. Hence, several studies from a health care payer perspective had to be included in our analysis as well. There is no official cost-effectiveness threshold in Switzerland, but as mentioned above, there was recently a discussion on this health topic initiated by a ruling of the Federal Court of Justice in that one life year saved is worth about CHF , 14 , However, in Switzerland this threshold is still arguable and there will be further discussions on this in the future.
To calculate the potential welfare impact of a new drug, it is required to know the ICER, respectively, ICUR of this drug compared to the standard treatment. The more patients benefit from a drug, the more attractive is it not only from a healthcare point of view but also economically.
Hence, the number of patients possibly benefiting from the drug was needed to calculate the welfare impact. The potential number of users includes all patients who could possibly be treated with a drug, but that is not always the same as actual users as not all people affected by a disease get treated. Therefore, the best way to assess the potential number of users is the estimated number of customers from the manufacturer. Because the number of all patients potentially benefiting of the respective drug was difficult to obtain, the actual number of users had to be used in most cases.
Only for four different drugs, namely conjugated vaccine, ibandronate, atorvastatin, and memantine, the information about the potential number of users was directly provided from the manufacturer. For risperdal and mimpara, the number of drug packages sold in was provided by the pharmaceutical manufacturer IMS Health sales figures and the number of actual users was calculated indirectly based on the usual dosage prescribed For the other drugs, the number of actual users was provided by the largest health insurance group in Switzerland, Helsana.
- Seduction and Snacks (Chocolate Lovers #1).
- HIDDEN (Marchwood Vampire Series Book 1).
- Outward Bound (Oberon Modern Plays)!
- Vergiß, wenn du leben willst (Romantik Thriller, Unheimlich) (German Edition);
These numbers were not presented in the results due to confidentiality reasons. The benefit from a drug also depends on the duration of the effect, in this case approximately the time horizon which was either 1 year, as long as the duration of the treatment or longer used in the cost-effectiveness models, which was also retrieved from the published literature.
Finally, the potential Swiss welfare impact in of a new drug was calculated by using the following equation developed by Tsiachristas et al. Second, the result was multiplied with the additional QALYs gained or lost by the new drug divided by the time horizon to get the additional QALYs gained or lost in 1 year and last, the result was multiplied with the number of users. Uncommonly, some new drugs do not only have better outcomes, i. Including only cost-effectiveness studies performed from a Swiss perspective would have been preferred.
Due to the fact that only few cost-effectiveness studies have been conducted in a Swiss setting, most cost-effectiveness studies included in our analysis were studies from foreign countries. Accordingly, there was a need to adjust the data to Switzerland before running the equation.
A univariate sensitivity analysis was conducted. The formula shows that varying the QALY effect and the number of users to the same extent would lead to the same welfare impact. Titles and abstracts of all references were screened to identify cost-effectiveness and cost—utility analyses. Full-texts were considered for the final inclusion of 31 studies Table 1 , of which 29 were conducted in foreign settings and only two studies that also met the inclusion criteria were conducted in a Swiss setting.
There was no need for adjustment of the data of these two studies 28 , For every drug, the welfare impact was calculated separately according to the formula described before. Generally, the results of the individual drugs differed broadly Table 2. There were some drugs which did not generate much potential welfare gain over 1 year compared to the standard treatment, e. Then, there were drugs where the evidence of potential welfare gains with the introduction of these drugs was much higher, e.
Nevertheless, each of the 31 reviewed drugs generated a positive result, meaning a clear welfare gain, except one of the drugs.
The introduction of cinacalcet mimpara to the Swiss market resulted in a monetary loss compared to the standard treatment. To obtain the total welfare impact for the Swiss economy due to the introduction of innovative drugs to the Swiss market, all results were summed up, which led to a total potential welfare gain of CHF This amounted to about 0. Table 2.